Patent estate

Acacia Research — Patent Portfolio

1 drug with active patents · 16 active patents · 0 expired · 0 biologics with BPCIA exclusivity

AI-enriched 16/16 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

§
Strategic Patent Estate Brief
AI-grounded executive summary · generated 2026-05-16

Verdict The Acacia Research portfolio is moderately vulnerable with an average vulnerability score of 70, and the company faces a significant cliff year in 2031 with 1 drug losing exclusivity, including Barhemsys.

Portfolio overview Acacia Research has a total of 1 drug with patents, out of which 1 is protected by 16 active US patents. The company's portfolio is relatively small, with no expired US patents and an average vulnerability score of 70. The majority of the patents (11 out of 16) are vulnerable, while none are considered ironclad. The company does not have any biologics in its portfolio.

Cliff calendar The company faces a significant cliff year in 2031, with 1 drug losing exclusivity, including Barhemsys. This year will see the loss of exclusivity for 1 drug, impacting the company's revenue.

Most exposed drugs The top drug facing near-term loss of exclusivity is Barhemsys, with an earliest active patent expiry date of 2031-03-10, an average vulnerability score of 70, and no annual revenue data available. This drug is protected by 16 active US patents.

Biologic exclusivity Acacia Research does not have any biologics in its portfolio, and therefore, there are no biologics with BPCIA 12-year reference product exclusivity.

Strategic implications The company faces a total revenue at risk of $0 in the next 5 years. Given the company's portfolio, it may consider lifecycle moves such as subQ switches, label extensions, or combination filings to maintain revenue and competitiveness.

Sources: FDA Orange Book · FDA Purple Book · INPADOC family · USPTO · vulnerability scoring. Not legal advice.

Loss of exclusivity calendar · next 12 years

Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.

1 2031 1 2034 1 2038

Patent estate by drug

Barhemsys (AMISULPRIDE)

Cliff 2031 · 5y
Formulation 2 Method of Use 14
  • US12194022 Vuln 81 2031-03-10
    This patent protects the use of amisulpride as an anti-emetic for treating nausea, vomiting, or retches.
  • US12194022 Vuln 81 2031-03-10
    This patent protects the use of amisulpride as an anti-emetic for treating nausea, vomiting, or retches.
  • US9889118 Vuln 76 2031-03-10
    This patent protects the use of amisulpride as an anti-emetic for treating nausea, vomiting, or retches.
See all 16 patents →

Patent classification breakdown · active patents

By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.

  • Method of Use 14 patents
  • Formulation 2 patents

Sources

  • FDA Orange Book — small-molecule patents listed against approved NDAs.
  • FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
  • USPTO Patent Public Search — title, abstract, claim text grounding.
  • AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track Acacia Research's patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export